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Genome sequencing efforts have revealed a strikingly large number of uncharacterized genes, including
poorly or uncharacterized metabolic enzymes, metabolites, and metabolic networks that operate in normal
physiology, and those enzymes and pathways that may be rewired under pathological conditions. Although
deciphering the functions of the uncharacterized metabolic genome is a challenging prospect, it also
presents an opportunity for identifying novel metabolic nodes that may be important in disease therapy.
In this review, we will discuss the chemoproteomic and metabolomic platforms used in identifying, charac-
terizing, and targeting nodal metabolic pathways important in physiology and disease, describing an inte-
grated workflow for functional mapping of metabolic enzymes.One of the most provocative findings to come out of the Hu-
man Genome Project was the discovery of a large number of
genes encoding proteins with unknown function, including
many uncharacterized enzymes that participate in the meta-
bolism of small-molecule metabolites (Venter et al., 2001).
These data revealed that our knowledge of cellular meta-
bolism was far less complete than we thought, and opened
up the possibility for yet undiscovered landscapes of metab-
olites and metabolic pathways. Indeed, even our under-
standing of well-characterized enzymes and their metabolic
functions in normal physiology remains largely incomplete,
especially in pathological states where these pathways may
be rewired or possess unique or novel functions. We are
now faced with the grand challenge of deciphering these un-
characterized metabolic networks and disentangling the
normal and disease roles of previously described metabolic
pathways. This undiscovered metabolic space presents an
exciting opportunity for discoveries in basic biology and
opens up the potential for targeting unique or novel metabolic
drivers of diseases related to dysregulated metabolism, such
as obesity, diabetes, atherosclerosis, cancer, infection, and
inflammatory diseases. Recent work has also demonstrated
the regulatory importance of metabolite flux through a given
pathway and the diverse roles of small biomolecules beyond
classical metabolism, including signaling and epigenetic, tran-
scriptional, and posttranslational regulation of critical cell
functions.
In this review, we will describe how innovative metabolic
mapping techniques have been used to successfully identify,
characterize, and pharmacologically target nodal metabolic
pathways important inmammalian physiology and disease. Spe-
cifically, we will discuss using chemoproteomic and metabolo-
mic approaches to globally assess enzyme activities, developing
chemical tools to interrogate enzyme function, and mapping the
metabolic pathways and metabolite-driven regulation controlled
by these enzymes.Chemistry & Biology 2Chemoproteomic Approaches to Assess the Functional
State of Enzymes in Complex Biological Systems
One of the key challenges of studying enzyme function has been
the ability to assay for explicit metabolic enzyme activities of
specific proteins in complex biological systems, especially for
enzymes with no known substrate or function. Developing a
method for global assessment of enzyme functionality remains
difficult because (1) enzymes can be regulated by posttransla-
tional events in vivo, which are poorly detected with standard
gene and protein expression profiling; (2) a substantial propor-
tion of the proteome remains functionally uncharacterized,
preventing the use of substrate-activity assays; and (3) the
physicochemical properties of many enzymes complicate their
analysis in biological samples (e.g., low abundance, difficulty in
enrichment).
One powerful method developed to address these challenges
is activity-based protein profiling (ABPP), a chemoproteomic
platform that uses activity-based probes (ABPs) that measure
the functional state of enzymes en masse in complex biological
samples (Evans and Cravatt, 2006; Moellering and Cravatt,
2012;Nomura et al., 2010a). AnABPconsists of a chemical group
that covalently reacts with the active sites of enzymes across a
particular enzyme class based on chemical reactivity within a
conserved catalytic architecture, andan analytical handle that fa-
cilitates a simultaneous read out enzyme activities (Figure 1A).
This analytical handle can be a fluorophore for depicting enzyme
activities, or a biotin handle for enrichment, identification,
and quantification of activities with mass spectrometry-based
proteomics (Figure 1B). To date, there are ABPs for more
than a dozen enzyme classes, including hydrolases, proteases,
kinases, phosphatases, glycosidases, caspases, oxygenases,
oxidoreductases, and nitrilases (Adam et al., 2001; Barglow
and Cravatt, 2006; Kato et al., 2005; Kidd et al., 2001; Liu et al.,
1999; Patricelli et al., 2007; Saghatelian et al., 2004a; Walls
et al., 2009; Weerapana et al., 2008; Williams et al., 2006; Xiao
et al., 2013).1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1171
activity-based probesA
reactive
group
analytical handle
(biotin, rhodamine)
ABPP proteomic strategiesB
caspases
nitrilases
kinases
metalloproteases
phosphatases
serine hydrolases
glycosidases
Rh
Rh
Rh
B
B
B
proteome
probe-labeled
proteome enzyme activity comparison
no
rm
al
di
se
as
e
SDS-PAGE
gel-based
ABPP
probe-labeled
proteome
on-bead
tryptic digest
avidin
enrichment
tryptic
peptides
m/z
m/z
m/z
sp
ec
tra
l c
ou
nt
s
no
rm
al
   
  
di
se
as
e
MS-based ABPP
LC/LC-MS/MS 
identification and quantification
ABPP-MudPIT
B
B
enzyme A
B
B
P
O
O
F TAG
( )n
N
NN
N
NH2
O
HOH
HH
HH
O
P
O
O
OH
P
O
OH
P
O
O
OH
O
TAG
N
SO3H
N
HO3S
H
N
O
OH
N
H
N
O
O O
OH
O
O
TAG
H
N
N
H
H
N
O
O O
Cl
R1
HN
O
X
NH TAG
P
O
OH
OH
Br
N
H
TAG
O
NO2
O2N
OO
FHO
O
OHN
HO
OH
OTAG
N
H
H
N
O
O
NH
O
TAG
O
OH
HO
Figure 1. Activity-Based Protein Profiling
(A) Examples of activity-based probes.
(B) Gel-based ABPP and ABPP-MudPIT platforms for fluorescent and mass-spectrometry-based analysis of enzyme activities. Rh, rhodamine; B, biotin.
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ReviewABPP overcomes many of the traditional challenges facing
enzyme activity assessment in complex samples. First, these
probes selectively and simultaneously label only active, but not
inactive, enzymes in a class, revealing changes in enzyme activ-
ity distinct from alterations in protein or transcript expression
level (Jessani et al., 2005; Kidd et al., 2001). Second, ABPs1172 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltenable enzyme activity assessment of uncharacterized enzymes
because these probes react with active sites based on class-
wide conserved chemical reactivity (Bachovchin et al., 2010;
Chiang et al., 2006; Weerapana et al., 2008). Third, ABPs allow
enrichment of specific classes of enzymes based on shared
functional properties, facilitating characterization of enzymesd All rights reserved
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Figure 2. Competitive ABPP Platforms
(A) ABPP-SILAC.
(B) Fluopol-ABPP.
(C) Isotope-ABPP.
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Reviewthat may be in low abundance or are embedded in a membrane
(Bachovchin et al., 2010; Weerapana et al., 2010).
Since the initial development by Cravatt and Bogyo, ABPP
platforms have incorporated chemical and analytical methods
that enable detecting enzyme activities in cells or in vivo, map-
ping sites of probe labeling in the proteome, and quantitative
assessment of enzyme activities. One of the most significant ad-
vances in ABPP platforms has been the complementation with
bioorthogonal ‘‘click chemistry’’ methods (Speers et al., 2003).
Bioorthogonal ABPs bearing an alkyne handle (instead of rhoda-Chemistry & Biology 2mine or biotin) can be treated in vitro, in situ, or even in vivo
to label active enzymes, facilitating target identification by sub-
sequently appending an analytical handle (e.g., rhodamine-
azide or biotin-azide) in vitro through copper-catalyzed ‘‘click
chemistry’’ (Speers et al., 2003). Another advancement of
the method involves coupling ABPP with stable isotopic labeling
of cells (ABPP-SILAC; Figure 2A) for quantitative proteomic
analysis of enzyme activities (Adibekian et al., 2011). To
improve the throughput of gel-based or mass spectrometry-
based ABPP, Bachovchin and colleagues adapted a method1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1173
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Reviewfor high-throughput screening using fluorescence polarization
(fluopol-ABPP; Figure 2B), primarily used for inhibitor screening
(Bachovchin et al., 2009). Recently, Weerapana and colleagues
developed an ABPP platform called tandem orthogonal proteol-
ysis ABPP (TOP-ABPP; Weerapana et al., 2008) to identify hy-
perreactivity and functionality of specific amino acid hotspots
within the proteome. In TOP-ABPP, alkyne-bearing ABPs or
reactivity-based probes (RBPs) are ‘‘clicked’’ to azide-bearing
tags that contain chemically or TEV protease cleavable linkers
and a biotin handle, allowing enrichment of probe-bound pro-
teins and subsequent release of probe-bound peptides upon
tandem digestions with trypsin and TEV protease. This TOP-
ABPP can be adapted for quantitative proteomics by incorpo-
rating an isotopically ‘‘heavy’’ labeled valine into the linker and
measuring the ratio of heavy to light labeling on a protein or at
a particular residue, a platform called isotopic TOP-ABPP (iso-
TOP-ABPP; Figure 2C; Weerapana et al., 2010). These ABPP
platforms have been successfully used to identify and charac-
terize enzyme activities in various human diseases, including
cancer, obesity, neurodegenerative diseases, and microbial
infection (Blais et al., 2010; Dominguez et al., 2014; Nomura
et al., 2010b, 2011a; Sadler et al., 2012; Singaravelu et al., 2010).
We review several representative examples of how ABPP
has been used to discover metabolic drivers of disease. In
particular, ABPP has been widely used to study the serine hydro-
lase superfamily of enzymes using the serine hydrolase-directed
ABPs fluorophosphonate (FP)-rhodamine and FP-biotin that
covalently phosphorylate the active site serine of nearly all of
the >200 serine hydrolase enzymes (Bachovchin et al., 2010;
Kidd et al., 2001; Liu et al., 1999). The serine hydrolase family
is one of the largest metabolic enzyme classes in themammalian
genome, though many of the family members are poorly or
incompletely characterized (Long and Cravatt, 2011). This class
encompassesmany types of enzymes, including hydrolases, es-
terases, lipases, proteases, thioesterases, and peptidases (Long
and Cravatt, 2011). Through mining serine hydrolase activities
with ABPP, several key metabolic or proteolytic drivers and bio-
markers of cancer have been identified, including KIAA1363,
monoacylglycerol lipase (MAGL), and retinoblastoma-binding
protein 9 (RBBP9; Chiang et al., 2006; Jessani et al., 2002;
Nomura et al., 2010b; Shields et al., 2010). Serine hydrolase
profiling was also used to discover that mutations in the
poorly characterized alpha/beta-hydrolase domain-containing
12 (ABHD12) in patients with a neurodegenerative disease
known as PHARC (polyneuropathy, hearing loss, ataxia, retinitis
pigmentosa, and cataracts) encoded a functionally inactive
ABHD12. Despite the lack of functional information regarding
ABHD12, Blankman and colleagues used ABPP to reveal inac-
tive ABHD12 in PHARC tissues and followed with metabolomic
techniques (discussed later in this review) to ascertain the func-
tion of ABHD12 and its role in PHARC pathogenesis (Blankman
et al., 2013). Serine hydrolase ABPs have also been used to iden-
tify important enzyme activities in bacterial and viral infections
such as carboxylesterase 1 (CES1) as an upregulated enzyme
activity in hepatitis C virus-infected hepatoma cells critical in
maintaining viral replication (Blais et al., 2010).
Many other ABPs have been generated and validated in com-
plex proteomes, including but not limited to (1) 2-oxoglutarate-
dependent oxygenase probes that employ a hydroxyquinoline1174 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Lttemplate coupled to a photoactivatable crosslinking group and
biotin handle (Rotili et al., 2011), (2) S-adenosylmethionine
(SAM)-dependent methyltransferase probes that consist of
S-adenosylhomocysteine analogs with amino linkers attached
to scaffolds containing photo-crosslinkers and a biotin handle
(Dalhoff et al., 2010), (3) a suite of bioorthogonal cytochrome
P450 ABPs against a wide cross-section of human P450s
(Wright and Cravatt, 2007; Wright et al., 2009), and (4) pargyline
and deprenyl-based bioorthogonal ABPs for monoamine oxi-
dase (Krysiak et al., 2012).
Bogyo and colleagues have been on the forefront of using
ABPP in depicting enzyme activities in cancer, generating
ABPs to track cysteine protease activity in cancer cell progres-
sion and proteosomal substrate specificity (Greenbaum et al.,
2000; Nazif and Bogyo, 2001). They have used quenched near-
infrared fluorescent ABP (qNIRF-ABP) to image cysteine prote-
ase activities in tumor xenografts in vivo in mice (Blum et al.,
2007) and have also developed a highly selective aza-peptidyl
asparadinyl epoxide qNIRF-ABP probe for legumain, a lyso-
somal cysteine protease upregulated inmultiple human cancers,
to depict tumors. Recently, they generated a caspase-directed
ABP to depict and quantify dexamethasone-induced apoptosis
in the thymus and Apomab-induced apoptosis in tumor xeno-
grafts in vivo in mice (Edgington et al., 2009).
ABPP platforms have also been extended to map the endog-
enous reactivity of the proteome with reactive electrophile-
based RBPs. Carroll and colleagues developed bioorthogonal
dimedone and sulfenome RBP probes that selectively react
with sulfenic acid cysteine modifications in the proteome and
used these probes to identify redox regulated pathways such
as the cysteine sulfenic acid-modified Gpx3 regulation of Yap1
in yeast, involved in regulating epidermal growth factor receptor
tyrosine kinase activity (Leonard et al., 2009; Paulsen and Car-
roll, 2009; Paulsen et al., 2012; Reddie et al., 2008; Seo and Car-
roll, 2011). Weerapana and colleagues used isoTOP-ABPP to
perform a massive quantitative proteomic profiling effort to
comprehensively profile hyperreactive cysteines in complex pro-
teomes, in which cells were first labeled with the cysteine-reac-
tive iodoacetamide-alkyne bioorthogonal probe. Proteomes
were then subjected to click chemistry with an isotopically-
labeled azide-linked cleavable biotin linker for enrichment and
release of cysteine-labeled peptides for subsequent analysis
by quantitative proteomics (Weerapana et al., 2010). The
authors uncovered a wide range of hyperreactive cysteines in
the proteome that were enriched in functional cysteines involved
in a wide range of activities, including nucleophilic and reductive
catalysis and sites of oxidative modification for both character-
ized and uncharacterized proteins across many different protein
classes, including some metabolic enzymes (Weerapana et al.,
2010). As demonstrated, isoTOP-ABPP is a broad and quantita-
tive approach capable of assessing the specific sites involved in
catalytic and regulatory function of large numbers of proteins
and metabolic enzymes.
As described above, ABPP has proven to be a powerful
technology in probing enzyme activities across a wide range of
enzyme classes and acrossmany physiological and cellular con-
texts, although like any approach, this technology is not without
its limitations. While many ABPs and RBPs have been devel-
oped by the chemical biology community, there are still manyd All rights reserved
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ABPP-basedmethods. Furthermore, whereas higher throughput
ABPP methods have been developed to screen large numbers
of compounds against one enzyme, the broad profiling of large
numbers of enzyme activities is still medium to low throughput
using gel-based and proteomic-based methods. These limita-
tions notwithstanding, as described here, ABPP is a versatile
platform can be used not only for target identification of enzymes
important in various diseases, but also for characterization of
unknown enzymes, for depicting enzyme activities, and even un-
covering hyperreactivity and functionality across the proteome.
Chemoprotomics for Developing Selective Small-
Molecule Inhibitors for Metabolic Enzymes
In addition to target discovery and imaging applications, ABPP
can also be used in a competitive mode to screen for enzyme in-
hibitors (Moellering and Cravatt, 2012). Inhibitor screening by
competitive ABPP exhibits several advantages over conven-
tional substrate assays. First, enzymes can be tested in native
proteomes without the need for recombinant expression or puri-
fication (Adibekian et al., 2011; Chang et al., 2011; Chiang et al.,
2006; Long et al., 2009), and second, inhibitors can be devel-
oped for uncharacterized enzymes without prior knowledge of
endogenous substrates (Adibekian et al., 2011; Bachovchin
et al., 2010; Chang et al., 2011; Chiang et al., 2006; Li et al.,
2007). Because inhibitors are tested against many enzymes
in parallel, inhibitor potency and selectivity can be simulta-
neously assessed, enabling subsequent medicinal chemistry
efforts to develop highly specific and effective enzyme inhibitors
(Chang et al., 2011; Long et al., 2009; Bachovchin et al., 2009,
2011; Adibekian et al., 2011). Thus, competitive ABPP provides
a universal assay for inhibitor discovery applicable to any
enzyme regardless of existing knowledge of its function as
long as there is a cognate ABP or RBP for the enzyme. Compet-
itive ABPP has emerged as a powerful approach for developing
potent and selective small-molecule inhibitors for both char-
acterized and uncharacterized enzymes, which have then
been used to inform the functions of metabolic enzymes in com-
plex systems. As described previously with standalone ABPP
approaches, competitive ABPP can be employed in a low-
throughput/high resolution mass spectrometry-based prote-
omics format with biotin-tagged activity-based probes using a
multidimensional protein identification technology (ABPP-Mud-
PIT), a medium-throughput gel-based format with fluorescent
activity-based probes (gel-based ABPP), or a high-throughput
screening format using fluorescence polarization with ABPs
against large compound libraries (fluopol-ABPP; Adibekian
et al., 2011; Bachovchin et al., 2009, 2010; Chang et al., 2011).
Competitive ABPP platforms have been remarkably success-
ful in generating small-molecule inhibitors of serine hydrolases
using the fluorophosphonate ABP. Chang and colleagues
developed the compound JW480, a highly selective, irrevers-
ible, in vivo efficacious, and orally bioavailable inhibitor of the
previously uncharacterized enzyme KIAA1363 that selectively
inhibited KIAA1363 activity in various tissues and in tumor xeno-
grafts, and impaired cancer cell migration and in vivo tumor
growth (Chang et al., 2011). Bachovchin and colleagues gener-
ated a library of >140 serine hydrolase inhibitors based on the
carbamate scaffold and tested all of these inhibitors against aChemistry & Biology 2library of >70 recombinantly expressed serine hydrolases in a
‘‘library versus library’’ screening effort, and successfully identi-
fied lead inhibitors for >40% of enzymes tested (Bachovchin
et al., 2010). Competitive ABPP platforms have also been used
to generate selective inhibitors for the serine hydrolases MAGL
and fatty acid amide hydrolase (FAAH), which degrade the endo-
cannabinoid signaling lipids 2-arachidonoylglycerol (2-AG) and
anandamide, respectively. MAGL inhibitors found through a
competitive ABPP screen of a structurally diverse carbamate
library and subsequent optimization led to the development of
the carbamate JZL184 as the first potent, selective, and in vivo
active MAGL inhibitor (Long et al., 2009). As described later in
this review, JZL184 has been used extensively to characterize
the biochemical functions of MAGL using metabolomics ap-
proaches, in the process revealing this enzyme as a therapeutic
target for cancer, inflammation and inflammatory diseases,
neurodegenerative diseases, anxiety, and pain. Ahn and col-
leagues have also used ABPP to generate the highly selective
and in vivo efficacious biaryl ether piperidine urea FAAH inhibitor
PF-3845. The authors also generated a bioorthogonal analog of
PF-3845 bearing an alkyne handle to show that PF3845-yne only
inhibited FAAH in vivo (Ahn et al., 2009).
Adibekian and colleagues used competitive ABPP-SILAC
platforms to show that the 1,2,3-triazole urea scaffold is ideal
for generating irreversible serine hydrolase inhibitors. The au-
thors generated a library of triazole urea inhibitors and optimized
the highly selective inhibitors AA74-1, AA39-2, and AA44-2 for
acyl peptide hydrolase, platelet activating factor acetylhydrolase
2, and uncharacterized hydrolase ABHD11, respectively (Adibe-
kian et al., 2011). Using this scaffold, Hsu and colleagues
generated the triazole urea inhibitors KT109 and KT172 for the
2-AG-synthesizing enzyme diacylglycerol lipase and confirmed
selectivity of these inhibitors in situ with ABPP-SILAC and in vivo
with ABPP-MudPIT (Hsu et al., 2012).
Screening large inhibitor libraries via high-throughput fluopol-
ABPP has led to identification of several small-molecule inhibi-
tors of metabolic enzymes. These include selective inhibitors
of anticancer targets protein methyl esterase 1, glutathione
transferase omega, and RBBP9, as well as an inhibitor for the
anti-inflammatory target protein arginine deaminase 4 (Bachov-
chin et al., 2009, 2011; Knuckley et al., 2010; Tsuboi et al., 2011).
As demonstrated above, competitive ABPP platforms are very
useful in developing inhibitors for metabolic enzymes. The ability
to assess inhibitor selectivity and target occupancy of inhibitors
in cells or even in vivo has been a particularly useful feature of this
approach toward providing highly specific chemical tools for
further biological discovery, leads for clinical development, and
biomarkers for inhibitor efficacy (Moellering and Cravatt, 2012).
Metabolomics to Annotate the Functions of
Uncharacterized Metabolic Enzymes
Chemoproteomic strategies such as ABPP have greatly
facilitated efforts to assess metabolic enzyme activities and
developing chemical tools to disrupt these activities in complex
biological systems. However, these strategies still need to be in-
tegrated with functional metabolomic approaches to decipher
the metabolites that are regulated by these enzymes and how
these metabolites and their associated metabolic pathways
are involved in (patho)physiology. The metabolome is generally1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1175
Figure 3. Targeted and Untargeted Metabolomic Profiling Platforms
Targeted metabolomic approaches oftentimes are performed by multiple reaction monitoring-based liquid chromatography-tandem mass spectrometry
methods. Untargeted metabolomic approaches are performed through collecting all mass spectra and using bioinformatics tools (e.g., XCMS) to identify,
integrate, and compare ions among comparison groups.
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include nutrients and their biosynthetic intermediates to provide
biomass (nucleic acids andDNA/RNA, amino acids and proteins,
fatty acids, and membrane lipids) and energy for cell growth and
function. However, this view is rapidly expanding to encompass
diverse metabolite constituents that serve as intracellular and
extracellular signaling molecules influencing physiological pro-
cesses such as neurotransmission (e.g., acetylcholine, gluta-
mate, 2-AG, anandamide; Fisher and Wonnacott, 2012; Hassel
and Dingledine, 2012; Kohnz and Nomura, 2014), inflammation
(e.g., sphingosine-1-phosphate, prostaglandins; Wymann and
Schneiter, 2008), and cancer (e.g., eicosanoids and lysophos-
phatidic acid; Mills and Moolenaar, 2003; Wang and Dubois,
2010), as well as endogenous nuclear hormone receptor ligands
that influence transcriptional regulation (Evans andMangelsdorf,
2014), and metabolites that confer posttranslational and epige-
netic regulation onto the proteome and genome (e.g., UDP-
GlcNAc and glycosylation, acetyl-coA and acetylation; Wellen
and Thompson, 2012). The metabolome is the functional output
of enzymes that generate, degrade, or convert biomolecules.
Thus functional metabolomic strategies, which uncover metabo-
lite changes that occur upon disruption of a specific metabolic
enzyme, are essential in deciphering biochemical functions and
(patho)physiological roles of enzymes in complex living systems.
Compared to the genome and the proteome, the metabolome
presents unique challenges for global analysis due to the sig-
nificant physicochemical diversity in metabolite size, molecular
weight, hydrophobicity, chemical stability, charge, volatility,
abundance, and ionization inherent in biological samples.
Several types of technologies and methodologies have been
used in metabolomic profiling to attempt near global detection
and analysis. Nuclear magnetic resonance, gas chromatog-
raphy-mass spectrometry, and liquid chromatography-mass
spectrometry are the most common techniques used for metab-1176 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltolomic profiling (Patti et al., 2012), and metabolomics analysis is
often performed using ‘‘targeted’’ or ‘‘untargeted’’ methods that
capture complementary information (Figure 3). Using targeted
metabolomic methods, a series of known metabolites are quan-
titatively measured, in which a mass spectrometer targets a list
of known metabolites by their mass-to-charge ratio (m/z) and/
or the transition of the ‘‘parent’’ m/z of metabolites to their
respective ms2 fragment ‘‘daughter’’ ions (known as multiple re-
action monitoring). Targeted metabolomics enables sensitive,
simultaneous quantification of hundreds of known metabolites
based on availability of standards, and is very useful in studying
defined metabolic pathways and quantifying specific, very low
abundance metabolites (Patti et al., 2012). However, targeted
metabolomic detection is restricted to quantifying known
metabolites for which there are existing standards. Untargeted
metabolomics can prove especially useful for uncovering the
function(s) of uncharacterized enzymes, when deciphering
unique and novel roles of previously characterized enzymes, or
identifying new metabolites. Untargeted metabolomic analyses
in which the mass spectrometer is set to scan a wide m/z range
and collect all mass spectra are used as a complementary
approach to targeted analyses to improve metabolome
coverage (Patti et al., 2012; Saghatelian and Cravatt, 2005;
Saghatelian et al., 2004b; Vinayavekhin et al., 2010). This large
amount of collected mass spectral data can then be analyzed
with bioinformatic platforms such as XCMS or MAVEN to iden-
tify, integrate, and compare all detectable ions to identify those
ions that are changed between comparison groups (Clasquin
et al., 2012; Patti et al., 2012; Smith et al., 2006; Tautenhahn
et al., 2012). This data can then be used to identify potentially
novel metabolites altered in abundance between groups using
metabolomic databases like METLIN, HMDB, and Lipid Maps
and traditional analytical chemistry methods (Fahy et al., 2007;
Nikolskiy et al., 2013; Smith et al., 2005; Wishart et al., 2013).d All rights reserved
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proaches have recently revealed the functions of previously
uncharacterized enzymes. Blankman and colleagues used
untargeted metabolomics to uncover the function of the previ-
ously uncharacterized enzyme a/b-hydrolase domain-contain-
ing 12 (ABHD12), a serine hydrolase mutationally inactivated
in patients with PHARC, as a lysophosphatidylserine (LPS)
hydrolase (Figure 4A; Blankman et al., 2013). Blankman and
colleagues showed that ABHD12-deficient mice show elevated
levels of the toll-like receptor agonist LPS, leading to neuroin-
flammation and motor and auditory defects reminiscent of
PHARC (Blankman et al., 2013).
Inhibitors developed through competitive ABPP platforms
have been used to interrogate the functions of uncharacterized
enzymes, which then led to insights into their pathophysiolog-
ical roles. Using untargeted metabolomics and the selective
KIAA1363 inhibitor AS115 developed by competitive ABPP
efforts, Chiang and colleagues discovered that KIAA1363 is a
2-acetyl-monoalkylglycerol (2-acetyl MAGE) hydrolase that gen-
erates monoalkylglycerol ether (MAGE) leading to the generation
of the oncogenic signaling lipid alkyl-lysophosphatidic acid,
which in turn fueled cancer cell pathogenicity and tumor growth
(Chiang et al., 2006).
Both targeted and untargeted metabolomics have been used
in conjunction with genetic manipulation to reveal the functions
of bacterial metabolic enzymes. Baran and colleagues used
the combined metabolomic platforms to characterize and vali-
date genes related to specific metabolite utilization in bacteria
by profiling libraries ofmutant strains inEscherichia coli andShe-
wanella oneidensis MR-1. Through this approach, the authors
identified genes with known functions as well as novel transport
proteins and enzymes required for utilization of tested metabo-
lites. Specifically, they uncovered a predicted ABC transporter
encoded by genes SO1043 and SO1044 required for citrulline
utilization and a predicted histidase encoded by the gene
SO3057 required for ergothioneine use by S. oneidensis (Baran
et al., 2013).
Metabolomics to Reveal Unique and Novel Roles for
Previously Characterized Enzymes
Whereas many ‘‘characterized’’ metabolic enzymes have puta-
tive biochemical functions, often these enzyme functions have
only been determined in vitro or may be described solely based
on sequence homology or by association with an enzyme family,
and may not have been validated in in vivo systems. Further-
more, enzymes may play alternate or additional roles or are
linked to different metabolic pathways depending on the tissue
or cell type, or in dysregulated and rewired disease states. Func-
tional metabolomics has proven critical in mapping rewired, re-
tasked, or novel functions of enzymes in tissue- or cell-specific
or disease-specific contexts.
De Carvalho and colleagues used an untargeted metabolomic
approach to describe the Mycobacterium tuberculosis enzyme
Rv1248c, which was characterized at the time as a thiamine
diphosphate-dependent a-ketoglutarate decarboxylase. Using
metabolomic approaches, the authors found that Rv1248c was
misannotated and that its actual function was to catalyze the
conjugation of a-ketoglutarate and glyoxylate to yield 2-hy-
droxy-3-oxoadipate, which decomposes to 5-hydroxylevulinate,Chemistry & Biology 2possibly involved in glyoxylate detoxification, glutamine meta-
bolism, or heme biosynthesis (de Carvalho et al., 2010).
Targeted and untargeted metabolomics were also used to
show the tissue-specific and disease-specific roles of MAGL
in coordinating multiple lipid signaling pathways that underlie
inflammation, pain, mood, and cancer (Figure 4B). Competitive
ABPP was used to generate JZL184, the first selective MAGL in-
hibitor, subsequently used to show that MAGL blockade caused
large elevations in the levels of the endocannabinoid 2-AG
in mouse brain, leading to cannabinoid receptor type 1 (CB1)-
dependent antinociceptive, anxiolytic, and anti-inflammatory ef-
fects (Kinsey et al., 2009, 2010, 2011; Long et al., 2009; Sciolino
et al., 2011). Using both targeted and untargeted metabolomic
approaches, subsequent studies showed that MAGL blockade
in specific tissues such as brain, liver, and lung also decreased
arachidonic acid and arachidonic acid-derived pro-inflammatory
eicosanoids such as prostaglandins and thromboxanes. This
resulted in neuroprotective and hepatoprotective effects in
degenerative and inflammatory diseases through suppressing
inflammation, thereby linking anti-inflammatory endocannabi-
noid signaling to pro-inflammatory eicosanoid signaling through
MAGL (Long et al., 2009; Nomura et al., 2008a, 2008b, 2011a;
Schlosburg et al., 2010; Chen et al., 2012; Piro et al., 2012).
Metabolomics has also been fundamental in understanding
how cancer cells alter their metabolism to fuel their pathogenic
properties. In a very unique discovery of a neomorphic function
for a mutated enzyme, Dang and colleagues used untargeted
metabolomic profiling to show that a mutant form of the tricar-
boxylic acid cycle enzyme isocitrate dehydrogenase 1 (IDH1),
IDH1 R132H, found in multiple types of cancers, generated a
novel oncometabolite 2-hydroxyglutarate (2-HG) (Dang et al.,
2009), which in turn caused epigenetic changes that fuel cancer
progression (Xu et al., 2011).
Nomura and colleagues used untargeted metabolomic plat-
forms to find that MAGL plays a distinct role in regulating fatty
acid release for the generation of fatty acid-derived lysophos-
pholipids and eicosanoids that drive aggressive features in can-
cer (Nomura et al., 2010c, 2011b). In another example, Benjamin
et al. used targeted and untargeted metabolomic approaches to
show that inactivating the ether lipid-generating enzyme alkyl-
glycerone phosphate synthase (AGPS) in aggressive cancer
cells dramatically reduced structural and oncogenic signaling
ether lipid levels. AGPS inactivation also diverted the flux of
arachidonic acid away from other tumor-promoting signaling
lipids such as prostaglandins, and toward structural acylglycer-
ophospholipids, leading to impaired cancer pathogenicity and
tumorigenesis (Benjamin et al., 2013; Figure 4C).
Looking further at cancer metabolism, Locasale and Posse-
mato independently showed phosphoglycerate dehydrogenase
(PHGDH) is a critical metabolic node in cancer cells, diverting
glucose metabolism into serine and glycine metabolism
(Locasale et al., 2011; Possemato et al., 2011). Locasale and
colleagues used heteronuclear single quantum coherence
spectroscopy NMR and isotopic tracing using targeted liquid
chromatography-mass spectrometry-based metabolomics of
13C-glucose labeled cells to show significant 13C incorporation
into 3-phosphoserine and serine pathways through PHGDH
(Locasale et al., 2011). Using functional metabolomics, Locasale
and colleagues found that inactivating PHGDH in melanoma1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1177
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(A) ABHD12 was characterized as a LPS hydrolase. ABHD12 deficiency leads to an accumulation in LPS, activates toll-like receptor 2, induces neuro-
inflammation, and causes a neurodegenerative disease known as PHARC (retinitis pigmentosa, hearing loss, ataxia, cataract, and polyneuropathy).
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neurodegenerative diseases. In cancer, MAGL blockade leads to reduced fatty acids and fatty acid-derived signaling lipids such as prostaglandins and lyso-
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(C) In cancer, AGPS was shown to not only control ether lipid synthesis, but also fatty acid metabolism that balances structural lipids with signaling lipids that fuel
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Reviewcancer cells lowered phosphoserine levels and caused an accu-
mulation in glycolytic intermediates (Locasale et al., 2011). In
breast cancer cells, Possemato and colleagues used functional
metabolomics to show that nearly half of a-ketoglutarate was
derived from the serine pathway and that PHGDH inactivation
in breast cancer cells reduced the levels of multiple tricarboxylic
acid cycle metabolites, leading to impaired cancer pathogenicity
(Possemato et al., 2011).
Metabolomics has also been useful in defining metabolic
drivers of viral infection. Grady and colleauges used an siRNA
screen to show that argininosuccinate synthase 1 (ASS1) knock-
down increased virus yield. They subsequently used meta-
bolomic profiling to show that ASS1 inactivation resulted in a
metabolic signature that closely resembled herpes simplex
virus-1 infection, in which levels of aspartate, carbamoyl-aspar-
tate, one of the first committed metabolites on the pathway to
nucleotide synthesis, and nucleotides and their precursors
were reduced (Grady et al., 2013).
Collectively, targeted and untargeted metabolomic platforms
can be used to functionally characterize not only the substrate/
product relationships of metabolic enzymes, but also the meta-
bolic networks that theseenzymescontrol in (patho)physiologicalChemistry & Biology 21, September 18, 2014 ªsettings. These techniques have proven
useful in discovering the mechanisms
throughwhich these enzymes control dis-
ease progression and in elucidating the
therapeutic potential ofmanipulating spe-
cific metabolic pathways.
Posttranslational and Epigenetic
Regulation of the Proteome and
Genome by Metabolic Pathways
Whereas small-molecule metabolites
have long been known to confer post-
translational and epigenetic modifica-
tions onto the proteome and genome,
these types of regulation have been
considered to be primarily regulated by
the enzymes directly involved in adding
or removing these modifications. These
metabolites, their modifications, and their
respective enzymes include acetyl-CoA
and acetylation/deacetylation by ace-
tyltransferases and deacetylases, SAM
and methylation/demethylation by meth-
yltransferases and demethylases, and
ATP and phosphorylation/dephosphory-lation by kinases and phosphatases (Prabakaran et al., 2012).
However, recent studies have shown that the metabolic en-
zymes and metabolic fluxes that generate these cofactors may
play an important role in regulating the levels of posttranslational
and epigenetic modifications (Wellen and Thompson, 2012). This
realization brings forth the exciting prospect of controlling meta-
bolic, signaling, and transcriptional networks simultaneously
through directly manipulating metabolic pathways. Here, we
provide some recent examples of metabolite-driven protein
and gene regulation in controlling pathophysiological processes.
Chemoproteomic platforms can also be used to identify
metabolite-driven posttranslational modifications in the prote-
ome. Wang and colleagues used competitive isoTOP-ABPP
platforms to globally map the targets of 4-hydroxy-2-nonenal
(HNE), a common lipid product of lipid peroxidation, whereby
HNE was competed against iodoacetamide-alkyne labeling in
cells. The authors showed that a unique cysteine in ZAK kinase
was the most sensitive target to HNE, and suggested that ZAK
is a special node in MAPK signaling that is sensitive to oxidative
stress (Wang et al., 2014; Figure 5A).
Moellering and colleagues recently discovered a novel
posttranslational modification, 3-phosphoglyceryl-lysine (pgK),2014 Elsevier Ltd All rights reserved 1179
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(A) Mutant IDH1 R132H generates 2-HG, inhibiting histone demethylases to fuel cancer progression through multiple mechanisms.
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Reviewgenerated by nonenzymatic covalent lysine modifications
through the glycolytic intermediate 1,3-bisphosphoglycerate
(1,3-BPG), the product of glyceraldehyde 3-phosphate dehydro-
genase (Figure 5B). The authors showed that this modification
accumulated on several glycolytic enzymes in cells exposed to
high glucose, leading to inhibition of activity and redirection of
glycolytic intermediates to biosynthetic pathways that support
cancer cell pathogenicity (Moellering and Cravatt, 2013).
We described in the previous section how mutant IDH1 in
cancer cells generate the oncometabolite 2-HG that drives
cancer pathogenicity. Studies have shown that IDH1 mutations1180 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltare correlated with hypermethylation at specific loci known as
the CpG island methylator phenotype in glioma and that mutant
IDH1 causes hypermethylation at many genetic loci (Figure 6A;
Turcan et al., 2012). Work by Xu and colleagues and Lu and
colleagues have since shown that 2-HG acts as a competitive
inhibitor of multiple a-KG-dependent dioxygenases, and that
IDH1 mutations can impair histone demethylation resulting
in a block to cell differentiation (Lu et al., 2012; Xu et al.,
2011). A mutation in IDH1 generates the novel oncometabolite
2-HG, which then confers large-scale epigenetic alterations
altering the expression of large numbers of genes, thus linkingd All rights reserved
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Reviewcentral carbon metabolism to gene regulation and cancer
pathogenicity.
Recent studies have also highlighted the importance of acetyl-
CoA levels in histone acetylation and transcriptional regulation.
Tu and colleagues used 2D gas chromatography-mass spec-
trometry-based metabolomic profiling to show changes in
acetyl-CoA levels periodic with yeast cell cycle phase, suggest-
ing that acetyl-coA levels may control temporal regulation of cell
cycle processes (Tu et al., 2007). Subsequently, Cai and col-
leagues showed that an increase in acetyl-CoA levels led directly
to the Gcn5p/SAGA-catalyzed acetylation of histones at genes
important for growth, thus promoting growth transcriptional
programming in yeast and serving as a metabolic rheostat
to initiate cell growth through acetylation of specific histones
(Cai and Tu, 2011). Similarly, Wellen and colleagues showed
in mammalian cells that ATP-citrate lyase (ACL) influences cell
growth and differentiation through controlling acetyl-CoA levels,
driving nutrient-responsive histone acetylation and selective
gene expression prompting growth factor-induced increases in
nutrient metabolism and reprogramming of intracellular meta-
bolism to utilize glucose for ATP production andmacromolecular
synthesis (Figure 6B; Wellen et al., 2009).
In another example, Ulanovskaya showed that N-methyltrans-
ferase (NNMT) can also influence the histone methylation and
epigenetic regulation that drives cancer aggressiveness through
methylating nicotinamide to generate N-methylnicotinamide
(Figure 6C). This leads to reduced SAM levels, thus diverting
SAM methylation away from histone methylation. The authors
showed that NNMT overexpression leads to upregulation
of many tumor-promoting gene products including SNAI2,
TGFB2, and CNTN1, via the altered epigenetic landscape of
cancer cells (Ulanovskaya et al., 2013). Interestingly, Kraus and
colleagues showed that NNMT also alters epigenetic and meta-
bolic landscapes in white adipose tissue (Kraus et al., 2014).
Through these mechanisms, the metabolic enzyme NNMT regu-
lates metabolism and epigenetic regulation to drive both cancer
and obesity.
Future Challenges
The resurgence of interest in metabolism has spurred a rapid
pace of advancements in the decade following the completion
of the human genome project, providing insight into fundamental
biochemistry as well as revealingmechanistic details of diseases
with metabolic bases such as cancer, infection, and obesity and
diabetes. Development of innovative chemoproteomic and me-
tabolomic platforms has enabled the characterization and
description of enzyme function in complex living systems, the
metabolic pathways that these enzymes regulate, and even
metabolic pathway-driven posttranslational and epigenetic
regulation of the proteome and genome. Although these technol-
ogies have revealed previously uncharacterized aspects of
metabolism and clarified existing ones, the majority of the meta-
bolic map still remains obscured. Higher throughput technolo-
gies for metabolomics and improved genetic or pharmacological
manipulation of enzyme activities in complex systems are
required to decode the function of the currently concealedmeta-
bolic genome.
Furthermore, major challenges still exist in elucidating enzyme
function. While we have provided successful examples of char-Chemistry & Biology 2acterizing enzymes in complex living systems, there are at least
an equal number of examples from personal experience where
inactivating or overexpressing an enzyme causes no detectable
metabolomic changes upon metabolomic profiling. There are
many reasons that may account for this apparent metabolomic
intransigence including technical and methodological limitations
such as (1) extraction procedures and LC/MS chromatography
conditions that confer metabolite instability; (2) the metabolites
regulated by the enzyme are too low abundance or are otherwise
undetectable by traditional metabolomicmethods (e.g., does not
ionize well, not volatile, or does not have a derivatization method
that improves detection); and (3) the metabolite change may be
localized to a specific cell type in a tissue or a specific intracel-
lular compartment and the metabolite changes are masked by
the remainder of the extracted metabolome. Elucidating enzyme
function is also complicated by (4) mischaracterized enzymes
that may be described as acting on a specific class of small-
molecule metabolites but may actually be operating on alterna-
tive metabolite classes or even protein, peptide, or genomic
substrates that may not be amenable to analysis by metabolo-
mic platforms; and (5) enzymes that may be acting on a yet
unknown posttranslational protein modification.
The information quality challenge of mischaracterized en-
zymes is likely a larger problem than currently appreciated,
as many enzymes are named based on sequence homology
to other proteins, but may not share similar substrate speci-
ficity. Metabolomic approaches are not amenable for substrate
profiling of larger substrates such as protein, peptides, and post-
translational modifications. Nonetheless, innovative protease
and peptidase substrate profilingmethods have been developed
to functionally define metabolic enzymes that may have protein
and peptide substrates, including subtiligase-mediated degra-
domic strategies, protein topography and migration analysis
platform, and peptidomic profiling methods (Dix et al., 2008,
2012; Kim et al., 2012; Mahrus et al., 2008; Nolte et al., 2009;
Tinoco et al., 2010). Although there are innovative proteomic
methods for mapping well-characterized posttranslational
modifications such as phosphorylation and acetylation by phos-
phoproteomic or acetylomic methods (Choudhary and Mann,
2010), unfortunately, there are currently few to no methods
for characterizing the functions of enzymes that act on unknown
posttranslational modifications, because there are currently no
proteomic strategies for globally identifying novel or unknown
protein modifications across the proteome.
What is quite clear is that achieving the goal of large-scale
functional characterization and description of metabolic en-
zymes in complex physiological and disease systemswill require
integrating multidimensional metabolic mapping technologies.
This will likely include the chemoproteomic and functional me-
tabolomic approaches described here in addition to newly devel-
oped chemical strategies that will expand our access into protein
function, our ability to generate pharmacological tools, and our
capacity to accelerate throughput of these analyses. These ad-
vances, coupled with increased resolution and depth of analyt-
ical platforms will support our drive to interrogate the unexplored
aspects of the metabolome, proteome, and peptidome. The
complex interplay between enzyme function, metabolomic land-
scape, posttranslational and epigenetic regulation, and metabo-
lite-protein-signaling networks described in this review presents1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1181
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Reviewa great challenge for scientists, but also offers exciting opportu-
nities to understand complex biology and treat disease by un-
derstanding fundamental metabolic function.
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